ILMN vs A vs RGEN Stock Comparison

Illumina, Agilent Technologies and Repligen Prices as of Oct 27, 2026 Peers: Industry group
1 more company in this comparison (TECH) Create a free account to keep reading and compare up to 10 companies.
ILMN Illumina, Inc.
$279.47 +3.5% 1M +178.5% 1Y
Market cap
$42.20B
P/E
51.2x
Revenue (TTM)
$4.49B
Div. yield
–
Life Sciences Tools Healthcare
4 wins
A Agilent Technologies, Inc.
$177.48 +2.7% 1M +21.1% 1Y
Market cap
$50.04B
P/E
34.8x
Revenue (TTM)
$7.37B
Div. yield
0.58%
Life Sciences Tools Healthcare
6 wins
RGEN Repligen Corp
$175.80 -7.3% 1M +9.1% 1Y
Market cap
$9.92B
P/E
–
Revenue (TTM)
$805.61M
Div. yield
–
Life Sciences Tools Healthcare
1 win

Head to Head

11 decided of 12

Agilent Technologies leads on 6 of the 12 questions below (Agilent Technologies 6, Illumina 4, Repligen 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionILMNARGENLeader
Larger companyMarket capitalisation $42.20B $50.04B $9.92B A
Cheaper on earningsLower P/E, profitable companies only 51.2x 34.8x -840.2x A
Cheaper on forward earningsLower price / next fiscal year consensus EPS 56.0x 27.1x 90.6x A
Faster revenue growthRevenue growth, trailing twelve months +4.9% +8.6% +13.8% RGEN
More profitableNet margin, trailing twelve months 18.4% 19.5% — A
Better return on capitalReturn on invested capital 15.1% 13.1% — ILMN
Less leveragedLower net debt / EBITDA 0.7x 1.1x — ILMN
Higher dividend yieldTrailing dividend yield — 0.58% — –
Better 1-year returnPrice return, last 12 months +178.5% +21.1% +9.1% ILMN
Better 5-year returnAnnualised price return, 5 years -7.0%/yr +2.6%/yr -9.5%/yr A
Less volatileAnnualised volatility, 1 year 50.4% 32.4% 46.3% A
Higher overall scoreMean of the five percentile scores vs peers 66/100 62/100 56/100 ILMN

Percentile Scorecard

ILMNARGEN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisILMNARGEN
Valuation 51 #111 of 227 58 #97 of 227 43 #129 of 227
Growth 45 #120 of 219 38 #137 of 219 31 #152 of 219
Profitability 97 #8 of 206 91 #20 of 206 68 #66 of 206
Financial Health 51 #117 of 238 55 #107 of 238 83 #41 of 238
Shareholder Returns 84 #23 of 134 71 #40 of 134 –
Overall 66 62 56
  • ILMN ranked among 247 companies in Medical Devices and Diagnostics
  • A ranked among 247 companies in Medical Devices and Diagnostics
  • RGEN ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodILMNARGENSPY
1 month +3.5%+2.7%-7.3% -0.2%
3 months +44.8%+26.3%+21.0% +3.9%
6 months +120.2%+54.5%+49.7% +8.2%
Year to date +113.1%+30.4%+7.3% +12.9%
1 year +178.5%+21.1%+9.1% +12.3%
3 years +163.0%+72.7%+47.0% +87.4%
3 years, per year +38.1%+20.0%+13.7% +23.3%
5 years -30.5%+13.9%-39.4% +67.9%
5 years, per year -7.0%+2.6%-9.5% +10.9%
10 years +106.3%+309.1%+513.8% +261.1%
10 years, per year +7.5%+15.1%+19.9% +13.7%

Risk

MeasureILMNARGENSPY
Volatility, 1Y 50.4%32.4%46.3% 12.7%
Downside volatility, 1Y 39.1%27.5%46.8% 12.7%
Beta vs S&P 500, 1Y 0.820.881.21 1.00
Return / volatility, 1Y 3.540.650.20 0.97
Max drawdown, 5Y -82.9%-39.6%-66.2% -25.4%
From 52-week high -4.8%-0.1%-9.6% -1.2%
52-week high $293.69$177.72$194.57 $779.14
52-week low $95.03$110.24$102.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleILMNARGEN
P/E now vs peer median 51.2xmedian 29.6x 34.8xmedian 29.6x -840.2xmedian 29.6x
P/S now vs peer median 9.4xmedian 2.9x 6.8xmedian 2.9x 12.3xmedian 2.9x
EV/EBITDA now vs peer median 37.3xmedian 17.4x 27.3xmedian 17.4x —median 17.4x
P/FCF now vs peer median 45.3xmedian 22.3x 39.5xmedian 22.3x 98.1xmedian 22.3x
P/B now vs peer median 14.9xmedian 2.3x 6.8xmedian 2.3x 4.7xmedian 2.3x
PEG now vs peer median 1.70median 1.04 3.54median 1.04 29.56median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsILMNARGEN
Revenue $4.49B $7.37B $805.61M
Gross profit $2.98B $3.97B –
Operating income $882.00M $1.64B $18.24M
Net income $825.00M $1.44B $26.59M
Free cash flow $931.00M $1.27B –
R&D $960.00M $485.00M $56.43M
EPS (diluted) $5.39 $5.09 $-0.21
Cash & equivalents $1.04B $1.76B $726.96M
Total debt $1.99B $3.95B –
Shares (diluted) 153.00M 283.00M 56.64M
Enterprise value $36.97B $42.93B $9.92B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricILMNARGEN
P/E 51.2x 34.8x -840.2x
P/FCF 45.3x 39.5x 98.1x
P/Operating cash flow 38.5x 31.1x 76.4x
P/S 9.4x 6.8x 12.3x
P/B 14.9x 6.8x 4.7x
P/Tangible book 17.4x 7.8x 5.6x
EV/EBITDA 37.3x 27.3x –
EV/EBIT 48.8x 31.9x –
EV/Revenue 9.6x 7.1x 12.3x
EV/FCF 46.2x 41.2x –
EV/Operating cash flow 39.3x 32.5x 76.4x
PEG (3Y EPS CAGR) 1.70 3.54 29.56

Growth

14 metrics
MetricILMNARGEN
Revenue growth (1Y) 4.9% 8.6% 13.8%
Revenue CAGR (3Y) -1.0% 1.8% 7.3%
Gross profit growth (1Y) 4.6% 11.2% –
Gross profit CAGR (3Y) 2.9% 3.7% –
Operating income growth (1Y) -31.8% 13.5% 2,185%
Operating income CAGR (3Y) 28.3% 5.1% -40.5%
Net income growth (1Y) -34.4% 18.0% 1,430%
Net income CAGR (3Y) 30.0% 8.3% -35.9%
EPS growth (1Y) -32.7% 18.9% -777.9%
EPS CAGR (3Y) 30.1% 9.8% -28.4%
Operating cash flow growth (1Y) -5.1% 7.6% -0.8%
Operating cash flow CAGR (3Y) 38.1% -1.9% -4.0%
Free cash flow growth (1Y) -9.7% 16.5% –
Free cash flow CAGR (3Y) 105.0% -3.7% –

Profitability

14 metrics
MetricILMNARGEN
Gross margin 66.4% 53.8% –
EBITDA margin 25.7% 25.9% –
Operating margin 19.6% 22.2% –
Pretax margin 22.6% 22.5% –
Net margin 18.4% 19.5% –
FCF margin 20.7% 17.2% –
Operating cash flow margin 24.4% 21.8% 16.1%
Return on equity 29.9% 19.9% 1.3%
Return on assets 12.5% 10.7% 0.9%
Return on invested capital 15.1% 13.1% –
Return on capital employed 17.5% 14.6% –
Asset turnover 0.7x 0.5x 0.3x
Cash conversion (OCF / net income) 1.3x 1.1x 4.9x
Stock comp / revenue 5.9% 1.8% 4.2%

Financial Health

11 metrics
MetricILMNARGEN
Debt / assets 29.9% 28.3% –
Debt / equity 0.7x 0.5x –
Net debt / EBITDA 0.7x 1.1x –
Debt / FCF 2.1x 3.1x –
Liabilities / assets 57.3% 47.3% 28.5%
Equity / assets 42.7% 52.7% 71.5%
Interest coverage 8.9x 15.5x –
Current ratio 1.8x 2.1x 9.9x
Quick ratio 1.2x 1.4x –
Cash ratio 0.7x 0.8x –
Altman Z-score 7.97 5.86 –

Shareholder Returns

7 metrics
MetricILMNARGEN
Dividend yield – 0.6% –
Net buyback yield 1.2% 0.6% –
Shareholder yield 1.2% 1.2% –
Payout ratio (earnings) – 19.9% –
Payout ratio (FCF) – 22.6% –
Dividend growth (1Y) – 2.1% –
Dividend CAGR (3Y) – 3.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusILMNARGEN
Forward P/E 56.0xFY2026 27.1xFY2026 90.6xFY2026
EPS, next fiscal year $4.99FY2026 $6.54FY2026 $1.94FY2026
EPS growth, next FY +3.1%FY2026 +17.0%FY2026 +13.5%FY2026
EPS growth, the year after +25.7% +0.3% +29.4%
Revenue, next fiscal year $4.52BFY2026 $7.87BFY2026 $773.94MFY2026
Revenue growth, next FY +4.1%FY2026 +15.3%FY2026 +4.8%FY2026
Revenue growth, the year after +12.0% -5.6% +35.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersILMNARGEN
Held by institutions 100.0% 92.6% 100.0%
Institutions holding 933 1,123 482
Change in shares held, QoQ +0.0% +3.2% +1.2%
Institutions buying 463 600 272
Institutions selling 330 350 141
Buyers to sellers 1.40 1.71 1.93

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ILMNARGEN
ILMN 1.00 0.48 0.41
A 0.48 1.00 0.61
RGEN 0.41 0.61 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ILMN, A and RGEN?

Agilent Technologies (A) is the largest by market capitalisation: Illumina (ILMN) $42.20B, Agilent Technologies (A) $50.04B, Repligen (RGEN) $9.92B.

Which stock is cheaper, ILMN, A and RGEN?

Agilent Technologies (A) trades on the lowest price-to-earnings ratio (Illumina (ILMN) 51.2x, Agilent Technologies (A) 34.8x, Repligen (RGEN) -840.2x). On next year's consensus earnings, Agilent Technologies (A) is cheapest (Illumina (ILMN) 56.0x, Agilent Technologies (A) 27.1x, Repligen (RGEN) 90.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Repligen (RGEN) grew revenue fastest over the trailing twelve months: Illumina (ILMN) +4.9%, Agilent Technologies (A) +8.6%, Repligen (RGEN) +13.8%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Illumina (ILMN) 18.4%, Agilent Technologies (A) 19.5%). On return on invested capital, Illumina (ILMN) leads (Illumina (ILMN) 15.1%, Agilent Technologies (A) 13.1%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Illumina (ILMN) +178.5%, Agilent Technologies (A) +21.1%, Repligen (RGEN) +9.1%. Over five years, Agilent Technologies (A) compounded fastest (Illumina (ILMN) -7.0%/yr, Agilent Technologies (A) +2.6%/yr, Repligen (RGEN) -9.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Agilent Technologies (A) 0.58%. Illumina (ILMN) and Repligen (RGEN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Agilent Technologies (A) has been the steadiest (Illumina (ILMN) 50.4%, Agilent Technologies (A) 32.4%, Repligen (RGEN) 46.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ILMN, A and RGEN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.